Andrew Hilgenbrink

Jefferies & Company analysts David Windley, Timothy C. Evans and Andrew Hilgenbrink reiterated their Buy rating for shares of Pharmaceutical Product Development Inc (Nasdaq: PPDI), with a price target of $32 per share. The analysts said that Pharmaceutical Product Development Inc management has...

Analysts David Windley and Andrew Hilgenbrink at Jefferies & Company, Inc. have upgraded Warner Chilcott Ltd. (NASDAQ: WCRX) from Hold to Buy rating. The company's management efficient operation continues to drive upsides. As a result, the 2010 guidance looks conservative, according to analysts...